Medical Utility

  • Prediction of cardiovascular risk in men (Hazard Ratio greater than 15) for guidance of cardiovascular check-up
  • Prevention of disease: Identified risk can be counteracted with ACEi/ARB therapy – independent of blood pressure

sphingotest® vr-hGH Immunoassay

  • sphingotest® vr-hGH is an ultra sensitive assay for Human Groth Hormone (hGH), indicating the vascular risk
  • The only IVD method to determine the low fasting plasma levels in men
  • The sphingotest® vr-hGH Broschure can be downloaded here


  1. Hallengren E, Almgren P, Engström G, Hedblad B, Persson M, Suhr J, Bergmann A, Melander O. Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malmö Diet and Cancer study. J Am Coll Cardiol. 2014; 64(14):1452-60. PubMed PMID: 252776167.
  2. Ng LL, Bhandari SS, Sandhu JK, Quinn PA, Squire IB, Davies JE, Struck J, Bergmann A, Jones DJ. Growth hormone for risk stratification and effects of therapy in acute myocardial infarction. Biomarkers. 2015;20(6-7):371-5. doi: 10.3109/1354750X.2015.1093031. Epub 2015 Nov 2. PubMed PMID: 26525661.